Free University

Verisk Estimates Industry Insured Losses from Winter Storm Ciarán will Range from EUR 800 Million to EUR 1.3 Billion

Retrieved on: 
Wednesday, November 8, 2023
Storm, ALE, Structural Damage, Temperature, Pressure, Free University of Berlin, Wind, Domingos, Tree, Ohio River, EUR, Free University, VRSK

Ciarán began as a shallow low that developed over the Ohio Valley, U.S., on Sunday 29 October, associated with very strong temperature gradients in the region.

Key Points: 
  • Ciarán began as a shallow low that developed over the Ohio Valley, U.S., on Sunday 29 October, associated with very strong temperature gradients in the region.
  • On Wednesday 1 November, the storm explosively deepened by 34 mb in 24 hours over warm sea surface temperatures, classifying Ciarán as a bomb cyclone.
  • However, high-exposure regions in the area were spared the worst impacts from the storm.
  • Verisk’s modeled insured loss estimates do not include:
    Additional living expenses (ALE) for residential claims for all modeled countries, except the UK

EQS-News: Wellington Partners promotes Johannes Fischer and Varun Gupta to Partner

Retrieved on: 
Tuesday, November 7, 2023
NYRA, Wellington Partners, Doctor of Medicine, L.E.K. Consulting, Free University of Berlin, Doctor of Philosophy, MBA, IESE Business School, Rehabilitation, MMI, Free University, Master of Science, Investment, Therapy, Berlin, Institute of technology, Pharmaceutical industry, Neuroscience, Biochemistry, DACH, Biotechnology

Munich, Germany - Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced the promotion of Dr. Johannes Fischer and Dr. Varun Gupta to Partner, effective immediately.

Key Points: 
  • Munich, Germany - Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced the promotion of Dr. Johannes Fischer and Dr. Varun Gupta to Partner, effective immediately.
  • Johannes joined Wellington in 2020 supporting the firm’s existing medical device and digital health portfolio.
  • Prior to joining Wellington, Varun interned at Ysios Capital in Barcelona and assisted the investment team at Forbion in Amsterdam/Naarden.
  • Regina Hodits, Managing Partner of Wellington Partners, commented: “We are grateful for Johannes and Varun’s significant contribution during the past years.

Lakewood-Amedex Announces Leadership Changes

Retrieved on: 
Wednesday, November 1, 2023
Medical Affairs Bureau, Pharmacology, Exact Sciences (company), Bayer, Radiology, Infection, Organic chemistry, Therapy, Shirin David, Drug discovery, Science, technology, engineering, and mathematics, Publication, Drug, Inflammation, Internal medicine, Development, Drug development, Senior, Free University of Berlin, Research and development, University, DRS, Free University, CV, Pharmacy, Agent handling, Cancer, Doctor of Philosophy, Pharmaceutical industry, Management, Nursing, Research, Science, Pfizer

UNIVERSITY PARK, Fla., Nov. 1, 2023 /PRNewswire/ -- Lakewood-Amedex Inc., a privately held, clinical-stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins™, today announced that Peter B. Corr, Ph.D., who has served as board chairman since 2020, was named Executive Chairman and will assume the strategic responsibilities of former CEO Steve Parkinson who left the company at the request of the Board. Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP. He retired from Pfizer Inc. in 2006 where he was Senior Vice President for Science and Technology, in addition to leading worldwide pharmaceutical research and development for Pfizer. Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development. His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/

Key Points: 
  • Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP.
  • Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development.
  • His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/
    The Company also announced leadership promotions in the organization for Thomas Balzer, M.D., Ph.D., Senior Vice President for Clinical Development, and Kelvin Cooper, Ph.D., Vice President of Research and Development.
  • We look forward to their continued contributions as we work to advance our Research and Clinical Development programs."

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

Retrieved on: 
Monday, September 25, 2023
Health, General Health, Research, Science, Optical, Biotechnology, University of Antwerp, Thalassemia, University, Doctor of Philosophy, HIV, Free University of Brussels (1834–1969), Medicine, Biogen, Beth Israel Deaconess Medical Center, CMO, Teaching hospital, Harvard Medical School, Graves' ophthalmopathy, VUB, Patient, Progressive multifocal leukoencephalopathy, Sickle cell disease, R, Therapy, Free University, Safety, TED, Pharmaceutical industry, Viridian

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Sarah Gheuens, M.D., Ph.D., to its Board of Directors.
  • During her time at Agios, she has overseen early- and late-stage clinical development globally across multiple indications, including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
  • “I’ve dedicated much of my career to developing medicines for underserved patient populations across a range of therapeutic areas.
  • She also holds a Ph.D. in Medical Sciences from the University of Antwerp, Belgium, and a Master’s in Medical Sciences from Harvard Medical School.

Trethera Announces Appointment of Laurent Dubois to Board of Directors

Retrieved on: 
Wednesday, February 15, 2023
Prince Albert Fund, Medicine, King Baudouin Foundation, Prince, Partner, Laurent Dubois, Patient, Business, Airport, McKinsey & Company, Free University of Brussels (1834–1969), GE, Economics, GE HealthCare, Texaco, Laurent, TotalEnergies, Free University, Cancer, Medication, Pharmaceutical industry, Management

LOS ANGELES, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Laurent Dubois to the Trethera Board of Directors as an independent director.

Key Points: 
  • LOS ANGELES, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Laurent Dubois to the Trethera Board of Directors as an independent director.
  • A healthcare executive veteran with over two decades of experience at McKinsey & Company and GE Healthcare, Mr. Dubois also will chair the Board’s Compensation Committee.
  • Laurent is currently the CEO of ADB Safegate, a Carlyle portfolio company and the global leader in airside guidance technology for airports.
  • He also served on the selection committee of the Prince Albert Fund, a program of the King Baudouin Foundation.

Leading Employment Law Firm DLaw Hires Attorney Anna Walther To Continue to Protect California's Working Class

Retrieved on: 
Tuesday, January 10, 2023
Restaurant, Education, Human rights, Cesar Chavez (film), University, Civil and political rights, Courage, Yoga, Free University of Berlin, DNA, Hard, Multimedia, Walther, Society, Disability rights movement, Disability, JD, Public policy, USC, Abuse, Fruit, San Joaquin Valley, Camping, United Farm Workers, LGBTQ, Loyola Law School, Workplace, Notre Dame, Doctor of Law, Free University, Ridesharing company, Porcelain, Medicine

Walther is a respected lawyer who fights for low-wage Californians who are seeking justice for labor rights violations.

Key Points: 
  • Walther is a respected lawyer who fights for low-wage Californians who are seeking justice for labor rights violations.
  • Since 2015, DLaw has successfully helped collect over $625,000,000 for the California working class with high-profile class action lawsuit cases protecting hard-working employees.
  • "Hard work is woven within Walther's DNA, which makes her both a prolific attorney and perfect fit for the DLaw collective," said DLaw Founder Emil Davtyan.
  • Walther returned back home to Los Angeles to study law at Loyola Law School, earning her JD in 2011 and passing the bar that summer.

Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer

Retrieved on: 
Thursday, September 29, 2022
Development, Free University, Doctor of Philosophy, Twitter, Brain, FDA, Neurocrine Biosciences, Parkinson's disease, LinkedIn, Senior, Free University of Brussels (1834–1969), Tardive dyskinesia, Patient, Regulatory affairs, Pharmacy, Bristol Myers Squibb, Wyeth, NASDAQ, SAN, AbbVie, Multimedia, Lists of diseases, View, Intercept Pharmaceuticals, Pharmaceutical industry, Immunology, Neurocrine, Facebook

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams.

Key Points: 
  • SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company's executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams.
  • Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.
  • "Ingrid's deep experience in regulatory affairs will be invaluable to Neurocrine as we work to advance our pipeline in our quest to relieve suffering for people with great needs, but few options," said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences.
  • Prior to joining Neurocrine Biosciences, Dr. Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals,which she joined in 2016.

Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer

Retrieved on: 
Monday, September 12, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Precision medicine, Free University, Berlin, Hospital, Free University of Berlin, Company, Massachusetts General Hospital, Therapy, GlaxoSmithKline, Patient, Cancer, Golden Gate University, Janssen, Prostate cancer, M.B.A, Scorpion, EGFR, International business, Toxicity, Pharmaceutical industry, Development, Sanofi

Scorpion Therapeutics, Inc. (Scorpion Therapeutics), a pioneering oncology company redefining the frontier of precision medicine, today announced the appointment of Michael Streit, M.D., M.B.A as the Companys first Chief Medical Officer (CMO).

Key Points: 
  • Scorpion Therapeutics, Inc. (Scorpion Therapeutics), a pioneering oncology company redefining the frontier of precision medicine, today announced the appointment of Michael Streit, M.D., M.B.A as the Companys first Chief Medical Officer (CMO).
  • Michael is an industry veteran with extensive experience in bench to bedside oncology drug development.
  • He has also helped advance the field of personalized medicine by developing novel targeted therapies paired with companion diagnostic assays.
  • Dr. Streit brings over 20 years of oncology and clinical development expertise to Scorpion Therapeutics.

Climate Obsessions by Banks and Big Tech Censorship is Driving Energy Insecurity and Dangerous Public Policy says Friends of Science

Retrieved on: 
Thursday, June 23, 2022
Zero, Carbon, Climate change, Inquiry, COP27, Uncertainty, Google, Review, Big Tech, ISD, Union, Big Bank, Bank, Book, Compliance, Institute, Business Development Bank of Canada, Insurance, Science Society of China, Competitive Enterprise Institute, UNFCC, Disclosure, UN, Free University, Famine, Letter, YouTube, CO2, Friends, SEC, Facebook, International Financial Reporting Standards, Literature, Poverty, International, Financial Post, IFRS, Post, Climate, Risk, Renewable energy, EU

CALGARY, Alberta, June 23, 2022 /PRNewswire-PRWeb/ -- In response to the Bank of Canada's June 9th, 2022, Financial System Review, which focusses on household debt and claims the conflict between Russia and Ukraine "has also further added to the level of uncertainty around the transition to a low-carbon economy", Friends of Science Society has issued an open letter challenging the Bank's assumptions on climate and the alleged low-carbon transition.

Key Points: 
  • Banks obsessed with attempting to model climate risks and Net Zero energy transition is driving energy insecurity in the West says Friends of Science Society.
  • Big Tech censorship of dissenting views on climate change, their push for renewable energy and claims of operating on 100% renewables is misleading the public and creating heat-or-eat poverty.
  • These facts are inescapable, yet Big Banks and Big Tech are obsessed with climate change and energy policies that will astronomically drive up their own operational costs.
  • Friends of Science Society is an independent group of earth, atmospheric and solar scientists, engineers, and citizens that is celebrating its 20th year of offering climate science insights.

Nonacus Welcomes Johan Vanderhoeven as Director of Sales and Support, Accelerating Its Growth and Expansion Plans

Retrieved on: 
Tuesday, May 24, 2022
Free University, DNA, Biological engineering, Integrated DNA Technologies, Doctor of Philosophy, Leadership, Patient, Genetic testing, Free University of Brussels (1834–1969), Workflow, Translation, Research, Civil engineering, Saint-Sulpice, Liquid biopsy, Precision medicine, Support, Cancer, Diagnosis, Integration, CEO, Management

Johan brings over 16 years of sales and leadership experience in the life sciences and diagnostics area to Nonacus.

Key Points: 
  • Johan brings over 16 years of sales and leadership experience in the life sciences and diagnostics area to Nonacus.
  • Prior to joining Nonacus, Johan gained expertise growing and leading high-performance sales teams globally at Integrated DNA Technologies (Coralville, Iowa, USA) and Sophia Genetics (Saint-Sulpice, Switzerland).
  • Commenting on this appointment, CEO of Nonacus, Chris Sale said, "We are happy to welcome Johan to Nonacus.
  • I'm thrilled to contribute to this extraordinary mission and look forward to expanding our efforts globally", stated Johan Vanderhoeven, Director of Sales & Support, Nonacus.